Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma (neGLIO)

The goal of modern neurooncological surgery is to obtain maximum tumor resection while preserving neurological function. Parietal lobe gliomas often cause attention deficits (hemineglect) that are difficult to differentiate from other deficits. This study aims to evaluate the extent and variation over time of visuo-spatial deficits in patients undergoing surgical removal of parietal lobe gliomas. This will help characterize the cognitive profile of these patients to identify personalized treatment and rehabilitation paths.

Study Overview

• Status: Recruiting
• Conditions: Glioma; Unilateral Spatial Neglect (USN); Parietal Lobe Glioma; Visuspatial Deficit

Detailed Description

This is a single-centre, prospective, cross-sectional, observational study involving 40 patients with high- and low-grade parietal lobe glioma. The study investigates the prevalence of subjects who show a performance in cognitive visuo-spatial tests below the cut-off of the normative sample. It evaluates associations with patient-reported outcome measures (ADL, IADL), clinical-demographic aspects, radiological data (MRI), and histological/molecular data. Assessments occur at screening (pre-surgery), and at follow-up visits (3-4 months and 6 months post-surgery). Neuropsychological tests include Line Bisection, Bell and Letter Cancellation, Reading test, Apple Cancellation, and Fluff test.

• Study Type: Observational
• Enrollment (Estimated): 40

Contacts and Locations

• Study Contact: Name: Francesco Di Meco, MD; Phone Number: + 39 02.2394; Email: francesco.dimeco@istituto-besta.it

Study Locations

• Italy
  • Milan, Italy
    • Recruiting
    • Fondazione IRCCS Istituto Neurologico Carlo Besta
    • Contact: Francesco Di Meco, MD; Phone Number: + 39 02.2394; Email: francesco.dimeco@istituto-besta.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with suspected parietal lobe glioma

Description

Inclusion Criteria:

• Patients >18 years old
• Patients must understand the Italian Language
• Patients with suspected parietal lobe glioma

Exclusion Criteria:

• Tumor site other than parietal lobe.
• Patients who cannot undergo surgical resection (stereotactic/open biopsy).
• Patients who received a previous chemotherapy and/or radiotherapy treatment.
• Patients with a history of intracranial mass lesion or traumatic brain injury.
• Patients with a history of other CNS diseases (e.g., stroke, metastasis).
• Patients with diagnosis of neurodegenerative disease (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis).

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Visuospatial Deficit Prevalence	Prevalence of patients with a score below the cut-off in specific neuropsychological tests for visuo-spatial aspects (Line Bisection, Bell/Letter Cancellation, Apple Cancellation, Fluff Test) and the extent of change compared to baseline.	Baseline (pre-surgery), 3-4 months post-surgery, 6 months post-surgery.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Association with Radiological Data	Correlation between visuo-spatial deficit scores and MRI data (FLAIR volume, T1 contrast, necrosis, localization).	Up to 6 months post-surgery
Association with Clinical-Demographic Data	Correlation between visuo-spatial scores and hemispheric dominance, age, sex, and education.	Up to 6 months post-surgery.
Association with Performance Status	Correlation between visuo-spatial scores and Karnofsky Performance Status (KPS).	Time Frame: Up to 6 months post-surgery.
Association with Histological/Molecular Data	Correlation between visuo-spatial scores and tumor grade, histological and molecular features.	Up to 6 months post-surgery.

Collaborators and Investigators

• Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
• Investigators: Principal Investigator: Francesco Di Meco, MD, Fondazione IRCCS Istituto Neurologico Carlo Besta

Study record dates

Study Major Dates

• Study Start (Actual): December 3, 2024
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: December 3, 2025
• First Submitted That Met QC Criteria: December 3, 2025
• First Posted (Actual): December 16, 2025

Study Record Updates

• Last Update Posted (Actual): December 16, 2025
• Last Update Submitted That Met QC Criteria: December 3, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Glioma; Neuropsychological assessment; Parietal Lobe; Hemineglect; Visuospatial deficit
• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Glioma
• Other Study ID Numbers: neGLIO

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No